全文获取类型
收费全文 | 29691篇 |
免费 | 1552篇 |
国内免费 | 164篇 |
学科分类
医药卫生 | 31407篇 |
出版年
2023年 | 191篇 |
2022年 | 148篇 |
2021年 | 640篇 |
2020年 | 412篇 |
2019年 | 564篇 |
2018年 | 692篇 |
2017年 | 512篇 |
2016年 | 610篇 |
2015年 | 599篇 |
2014年 | 764篇 |
2013年 | 967篇 |
2012年 | 1581篇 |
2011年 | 1644篇 |
2010年 | 956篇 |
2009年 | 804篇 |
2008年 | 1430篇 |
2007年 | 1615篇 |
2006年 | 1591篇 |
2005年 | 1550篇 |
2004年 | 1506篇 |
2003年 | 1334篇 |
2002年 | 1347篇 |
2001年 | 962篇 |
2000年 | 967篇 |
1999年 | 843篇 |
1998年 | 332篇 |
1997年 | 262篇 |
1996年 | 264篇 |
1995年 | 197篇 |
1994年 | 194篇 |
1993年 | 167篇 |
1992年 | 555篇 |
1991年 | 516篇 |
1990年 | 500篇 |
1989年 | 482篇 |
1988年 | 426篇 |
1987年 | 417篇 |
1986年 | 413篇 |
1985年 | 398篇 |
1984年 | 238篇 |
1983年 | 192篇 |
1982年 | 107篇 |
1979年 | 180篇 |
1978年 | 113篇 |
1977年 | 107篇 |
1975年 | 87篇 |
1973年 | 95篇 |
1972年 | 91篇 |
1970年 | 109篇 |
1969年 | 92篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kazuya Inoue Naoki Suenaga Naomi Oizumi Hiroshi Yamaguchi Naoki Miyoshi Noboru Taniguchi Noriaki Matsumura Shuzo Morita Shimpei Kurata Yasuhito Tanaka 《Seminars in Arthroplasty》2022,32(2):252-257
BackgroundIn shoulder arthroplasty, bone resorption around the stem can lead to stem loosening and makes surgery difficult at the time of revision. Proximal bone resorption after reverse shoulder arthroplasty can cause instability because of a decrease of deltoid wrapping effect. As factors of the stem itself, such as stem coating, shape, length, and use of bone cement, may also affect bone resorption, a single-stem model should be used to compare bone resorptions between different pathologies and surgical procedures. However, to date, a few reports have compared these differences in detail using a single-stem model. Therefore, we investigated the prevalence and location of humeral bone resorption in a single-stem model.MethodsThe study included 100 shoulders that underwent anatomical total shoulder arthroplasty (TSA) or humeral head replacement (HHR) with a single uncemented humeral stem from 2008 to 2018. The patients were 31 men and 69 women. The mean age at surgery was 72.9 years (range, 41-86 years). The patients were divided into three groups: especially, 25, 61, and 14 shoulders received TSA for primary osteoarthritis without rotator cuff tears (TSA group), HHR using an anatomical head with rotator cuff repair for cuff tear arthropathy (CTA) (HHR group), and HHR using a CTA head without rotator cuff repair (CTA group), respectively. Patients were monitored for a mean of 56 months (range, 12-98 months). The location of bone resorption was divided into seven zones as follows: zone 1, greater tuberosity; zone 2, lateral diaphysis; zone 3, lateral diaphysis beyond the deltoid tuberosity; zone 4, tip of the stem; zone 5, medial diaphysis beyond the deltoid tuberosity; zone 6, medial diaphysis; and zone 7, calcar region. The degree of bone resorption was classified from grade 0 to 4.ResultsBone resorption of grade 3 or higher was significantly more frequent at the greater tuberosity in the HHR and CTA groups (P < .001 and P < .001, respectively) than that in the TSA group. Grade 4 bone resorption was significantly more frequent in the CTA than that in the TSA and HHR groups in zone 1 (P = .016 and P = .041, respectively).ConclusionThe state of attachment of the rotator cuff to the greater tuberosity might affect bone resorption at the greater tuberosity, such as the greater tuberosity after shoulder arthroplasty. In cases of shoulder arthroplasty for arthropathy with rotator cuff tear, performing rotator cuff repair might prevent bone resorption.Level of evidenceLevel IV; Prognosis Study 相似文献
2.
3.
4.
Shimon Kurasawa Takahiro Imaizumi Shoichi Maruyama Keitaro Tanaka Yoko Kubo Mako Nagayoshi Hiroaki Ikezaki Sadao Suzuki Teruhide Koyama Chihaya Koriyama Aya Kadota Sakurako Katsuura-Kamano Kiyonori Kuriki Kenji Wakai Keitaro Matsuo 《International journal of cancer. Journal international du cancer》2023,153(4):732-741
The association between kidney function and cancer incidence is inconsistent among previous reports, and data on the Japanese population are lacking. It is unknown whether kidney function modifies the cancer risk of other factors. We aimed to evaluate the association of estimated glomerular filtration rate (eGFR) with cancer incidence and mortality in 55 242 participants (median age, 57 years; 55% women) from the Japan Multi-Institutional Collaborative Cohort Study. We also investigated differences in cancer risk factors between individuals with and without kidney dysfunction. During a median 9.3-year follow-up period, 4278 (7.7%) subjects developed cancer. Moderately low and high eGFRs were associated with higher cancer incidence; compared with eGFR of 60-74 ml/min/1.73 m2, the adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) for eGFRs of ≥90, 75-89, 45-59, 30-44 and 10-29 ml/min/1.73 m2 were 1.18 (1.07-1.29), 1.09 (1.01-1.17), 0.93 (0.83-1.04), 1.36 (1.00-1.84) and 1.12 (0.55-2.26), respectively. High eGFR was associated with higher cancer mortality, while low eGFR was not; the adjusted subdistribution HRs (95% CIs) for eGFRs of ≥90 and 75-89 ml/min/1.73 m2 were 1.58 (1.29-1.94) and 1.27 (1.08-1.50), respectively. Subgroup analyses of participants with eGFRs ≥60 and <60 ml/min/1.73 m2 revealed elevated cancer risks of smoking and family history of cancer in those with eGFR <60 ml/min/1.73 m2, with significant interactions. Our findings suggest that the relationship between eGFR and cancer incidence was U-shaped. Only high eGFR was associated with cancer mortality. Kidney dysfunction enhanced cancer risk from smoking. 相似文献
5.
Takehiko Mori Souichi Shiratori Junji Suzumiya Mineo Kurokawa Motohiro Shindo Uchida Naoyuki Takenaka Katsuto Toshihiro Miyamoto Satoshi Morishige Makoto Hirokawa Takahiro Fukuda Yoshiko Atsuta Ritsuro Suzuki 《Hematological oncology》2020,38(3):266-271
Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome. 相似文献
6.
7.
Eric Wang Sydney X. Lu Alessandro Pastore Xufeng Chen Jochen Imig Stanley Chun-Wei Lee Kathryn Hockemeyer Yohana E. Ghebrechristos Akihide Yoshimi Daichi Inoue Michelle Ki Hana Cho Lillian Bitner Andreas Kloetgen Kuan-Ting Lin Taisuke Uehara Takashi Owa Raoul Tibes Iannis Aifantis 《Cancer cell》2019,35(3):369-384.e7
8.
9.
Hiroaki Soyama Morikazu Miyamoto Hiroko Matsuura Hideki Iwahashi Soichiro Kakimoto Hiroki Ishibashi Takahiro Sakamoto Taira Hada Jin Suminokura Masashi Takano 《Cancer chemotherapy and pharmacology》2020,85(5):941-947
The aim of this study was to investigate the association between changes in the levels of vascular endothelial growth factors (VEGFs) after treatment with bevacizumab and gemcitabine (Bev-Gem) and the clinical outcome. Platinum-resistant ovarian cancer patients treated with Bev-Gem therapy at our hospital between 2014 and 2018 were identified. Serum VEGF levels at the first and second treatment cycle were measured by ELISA. All patients were categorized into two groups—patients with > 50% decrease in serum VEGF-A levels (Group A) and patients with < 50% decrease serum VEGF-A levels (Group B). The association between clinical outcome and serum VEGF levels was investigated between the two groups. Among 18 patients, 10 were in Group A and 8 in Group B. Group A exhibited a lower response rate (0% vs.75% p < 0.01) and clinical benefit rate (60% vs.100% p = 0.02) than Group B. The median serum VEGF-A level of Group A before the first cycle of Bev-Gem therapy was higher than that in Group B (61.2 vs. 3.7 pg/mL, p < 0.01). Group A exhibited worse PFS (7 vs., 10 months, p < 0.01) and OS (17 vs. 26 months, p = 0.04) than Group B. There were more patients with > 10% increase in serum VEGF-B levels in Group A than in Group B (p < 0.01). The rapid decrease in VEGF-A levels and the resultant increase in serum VEGF-B levels might be associated with an unfavorable clinical outcome. Large-scale studies are needed to further examine these results. 相似文献